TSHA

Taysha Gene Therapies, Inc. [TSHA] Stock Forecast

Q: What is Taysha Gene Therapies, Inc. stock symbol ?

Taysha Gene Therapies, Inc. is a US stock, located in Dallas of Tx and trading under the symbol TSHA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TSHA Stock Summary

Earnings have grown 517.55% per last year.

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Earnings are expected to fall -100% next year

Profit margins (-15.32%) are lower than the previous year (-7.22%)

TSHA has less than 1 year of cash runway

Top 10 Correlated ETFs

TSHA

Top 10 Correlated Stocks

TSHA

In the News

TSHA Financial details

Company Rating

Strong Buy

Market Cap

549.83M

Income

-114M

Revenue

15.45M

Book val./share

0.4

Cash/share

0.77

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 May 2024

P/E

-1.1

Forward P/E

PEG

0.17

P/S

25.02

P/B

-4.91

P/C

2.96

P/FCF

-6.87

Quick Ratio

0.91

Current Ratio

0.95

Debt / Equity

0.56

LT Debt / Equity

EPS (TTM)

-1.37

EPS next Y

EPS next Q

EPS this Y

-75.13%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

-24.06%

EPS Q/Q

-127.96%

SMA20

SMA50

50%

SMA100

50%

Inst Own

159.8%

Inst Trans

7.39%

ROA

-112%

ROE

877%

ROC

-7.27%

Gross Margin

100%

Oper. Margin

-776%

Profit Margin

-1532%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.5-3.89

52W High

52W Low

RSI

Rel Volume

0.55

Avg Volume

2.77M

Volume

1.52M

Perf Week

-29.27%

Perf Month

-9.62%

Perf Quarter

2.82%

Perf Half Y

1.22%

Beta

0.262

Volatility

0.2%, 0.35%

Prev Close

-5.5%

Price

2.2775

Change

-7.04%

TSHA Financial Performance

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.04	0.07	0.04	0.04	0.02
Net income per share	-1.03	-0.32	-0.38	-0.93	0.26
Operating cash flow per share	0.25	-0.32	-0.29	-0.14	-0.09
Free cash flow per share	0.21	-0.38	-0.29	-0.17	-0.09
Cash per share	1.56	1	0.7	1.31	0.77
Book value per share	0.02	-0.24	-0.58	-0.39	0.4
Tangible book value per share	0.02	-0.24	-0.58	-0.39	0.4
Share holders equity per share	0.02	-0.24	-0.58	-0.39	0.4
Interest debt per share	1.08	0.97	0.95	0.46	0.23
Market cap	127.43M	50.48M	42.47M	397.21M	330.92M
Enterprise value	99.48M	46.9M	56.9M	292.12M	247.64M
P/E ratio	-0.55	-0.63	-0.43	-0.85	1.73
Price to sales ratio	50.93	10.73	17.73	83.69	91.82
POCF ratio	8.93	-2.5	-2.26	-22.13	-20.53
PFCF ratio	10.65	-2.1	-2.27	-18.52	-20.51
P/B Ratio	134.28	-3.38	-1.14	-8.09	4.42
PTB ratio	134.28	-3.38	-1.14	-8.09	4.42
EV to sales	39.76	9.97	23.76	61.55	68.71
Enterprise value over EBITDA	-5.38	-2.95	-2.49	-17.98	-16.05
EV to operating cash flow	6.97	-2.32	-3.03	-16.28	-15.36
EV to free cash flow	8.31	-1.95	-3.04	-13.62	-15.35
Earnings yield	-0.46	-0.4	-0.58	-0.29	0.14
Free cash flow yield	0.09	-0.48	-0.44	-0.05	-0.05
Debt to equity	63.15	-4	-1.6	-1.21	0.56
Debt to assets	0.47	0.59	0.73	0.3	0.16
Net debt to EBITDA	1.51	0.23	-0.63	6.47	5.4
Current ratio	1.54	1.33	1.07	0.95	4.06
Interest coverage	-69.25	-12.05	-16.24	11.05	-22.16
Income quality	-0.26	1.15	0.76	0.15	-0.34
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.93	1.86	2.5	1.81	1.86
Research and developement to revenue	5.54	2.66	8.26	2.48	3.52
Intangibles to total assets	-0.04	0	0	0	0
Capex to operating cash flow	-0.16	0.19	0	0.19	0
Capex to revenue	-0.92	-0.83	0.02	-0.74	0
Capex to depreciation	-6.34	-11.78	0.14	-10.57	-0.05
Stock based compensation to revenue	1.64	0.36	0.93	0.43	0.55
Graham number	0.62	1.3	2.23	2.86	1.52
ROIC	-0.71	-0.28	-0.57	-0.53	-0.12
Return on tangible assets	-0.44	-0.2	-0.3	-0.6	0.18
Graham Net	-0.66	-0.84	-1.15	-0.64	-0.25
Working capital	33.63M	17.9M	3.47M	-8.64M	112.43M
Tangible asset value	5.94M	-14.95M	-37.11M	-49.11M	74.94M
Net current asset value	-28.91M	-44.19M	-64.54M	-73.08M	-42.87M
Invested capital	63.15	-4	-1.6	-1.21	0.56
Average receivables	0	0	0	0	0
Average payables	13.1M	9.97M	9.88M	9.14M	6.94M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	586.74	1.28K	1.38K	2.04K	1.57K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.15	0.07	0.07	0.04	0.06
Inventory turnover	0	0	0	0	0
ROE	-61.18	1.34	0.66	2.38	0.64
Capex per share	-0.04	-0.06	0	-0.03	0

TSHA Frequently Asked Questions

What is Taysha Gene Therapies, Inc. stock symbol ?

Taysha Gene Therapies, Inc. is a US stock , located in Dallas of Tx and trading under the symbol TSHA

What is Taysha Gene Therapies, Inc. stock quote today ?

Taysha Gene Therapies, Inc. stock price is $2.2775 today.

Is Taysha Gene Therapies, Inc. stock public?

Yes, Taysha Gene Therapies, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.77M
Market Capitalization 549.83M
Employee 52
CEO Mr. Sean P. Nolan
Headquarters Dallas,TX,US
IPO Date 2020-09-24
Website https://www.tayshagtx.com

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.